Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

July 20, 2018 5:33 PM UTC

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis.

MorphoSys and Galapagos will receive €95 million ($111.1 million) up front and are eligible for €850 million ($993.8 million) in milestones, plus double-digit royalties. MorphoSys and Galapagos will split all payments evenly...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article